Literature DB >> 23713816

Clinical pharmacology = disease progression + drug action.

Nick Holford1.   

Abstract

Clinical pharmacology is concerned with understanding how to use medicines to treat disease. Pharmacokinetics and pharmacodynamics have provided powerful methodologies for describing the time course of concentration and effect in individuals and in populations. This population approach may also be applied to describing the progression of disease and the action of drugs to change disease progress. Quantitative models for symptomatic and disease-modifying effects of drugs are valuable not only for describing drugs and diseases but also for identifying criteria to distinguish between types of drug actions, with implications for regulatory decisions and long-term patient care.
© 2013 The Author. British Journal of Clinical Pharmacology © 2013 The British Pharmacological Society.

Entities:  

Keywords:  Alzheimer's; Parkinson's disease; depression; disease progression; osteoporosis

Mesh:

Year:  2015        PMID: 23713816      PMCID: PMC4294073          DOI: 10.1111/bcp.12170

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  55 in total

1.  Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.

Authors:  N Frey; C Laveille; M Paraire; M Francillard; N H G Holford; Roeline Jochemsen
Journal:  Br J Clin Pharmacol       Date:  2003-02       Impact factor: 4.335

2.  Interpreting the results of Parkinson's disease clinical trials: time for a change.

Authors:  Nick H G Holford; John G Nutt
Journal:  Mov Disord       Date:  2011-03-02       Impact factor: 10.338

Review 3.  Disease progression and neuroscience.

Authors:  Nick Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-04-17       Impact factor: 2.745

4.  Maximum likelihood estimation of long-term HIV dynamic models and antiviral response.

Authors:  Marc Lavielle; Adeline Samson; Ana Karina Fermin; France Mentré
Journal:  Biometrics       Date:  2011-03       Impact factor: 2.571

5.  Population pharmacokinetics and pharmacodynamics of thiopental: the effect of age revisited.

Authors:  D R Stanski; P O Maitre
Journal:  Anesthesiology       Date:  1990-03       Impact factor: 7.892

Review 6.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

7.  Disease progression meta-analysis model in Alzheimer's disease.

Authors:  Kaori Ito; Sima Ahadieh; Brian Corrigan; Jonathan French; Terence Fullerton; Thomas Tensfeldt
Journal:  Alzheimers Dement       Date:  2009-07-09       Impact factor: 21.566

8.  Magnitude and pattern of skeletal response to long term continuous and cyclic sequential oestrogen/progestin treatment.

Authors:  S Pors Nielsen; O Bärenholdt; F Hermansen; N Munk-Jensen
Journal:  Br J Obstet Gynaecol       Date:  1994-04

9.  Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.

Authors:  N H Holford; K E Peace
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

10.  The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods.

Authors:  L B Sheiner
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

View more
  10 in total

1.  The pharmaceutical industry needs more clinical pharmacologists.

Authors:  Richard Peck
Journal:  Br J Clin Pharmacol       Date:  2017-08-16       Impact factor: 4.335

2.  Pharmacometrics: so much mathematics and why planes achieve their destinations with almost perfect results ….

Authors:  Geoffrey K Isbister; Robert Bies
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

3.  Applying Beta Distribution in Analyzing Bounded Outcome Score Data.

Authors:  Chuanpu Hu; Honghui Zhou; Amarnath Sharma
Journal:  AAPS J       Date:  2020-03-17       Impact factor: 4.009

4.  Comparison of Model Averaging and Model Selection in Dose Finding Trials Analyzed by Nonlinear Mixed Effect Models.

Authors:  Simon Buatois; Sebastian Ueckert; Nicolas Frey; Sylvie Retout; France Mentré
Journal:  AAPS J       Date:  2018-03-29       Impact factor: 4.009

5.  Improving categorical endpoint longitudinal exposure-response modeling through the joint modeling with a related endpoint.

Authors:  Chuanpu Hu; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-11-20       Impact factor: 2.745

6.  Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models.

Authors:  Meindert Danhof
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-08-30       Impact factor: 2.745

7.  Moderate to severe HIV-associated neurocognitive impairment: A randomized placebo-controlled trial of lithium.

Authors:  Eric H Decloedt; Carla Freeman; Fleur Howells; Martine Casson-Crook; Maia Lesosky; Eleni Koutsilieri; Simon Lovestone; Gary Maartens; John A Joska
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

8.  Modeling Disease Progression: Angiotensin II Indirectly Inhibits Nitric Oxide Production via ADMA Accumulation in Spontaneously Hypertensive Rats.

Authors:  Haidong Wang; Hao Jiang; Haochen Liu; Xue Zhang; Guimei Ran; Hua He; Xiaoquan Liu
Journal:  Front Physiol       Date:  2016-11-17       Impact factor: 4.566

Review 9.  Liver Microphysiological Systems for Predicting and Evaluating Drug Effects.

Authors:  Alexandre J S Ribeiro; Xinning Yang; Vikram Patel; Rajnikanth Madabushi; David G Strauss
Journal:  Clin Pharmacol Ther       Date:  2019-06-04       Impact factor: 6.875

10.  A Population Approach to Characterize Interferon Beta-1b Effect on Contrast Enhancing Lesions in Patients With Relapsing Remitting Multiple Sclerosis.

Authors:  A Gulati; F Bagnato; P Villoslada; N Velez de Mendizabal
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-04-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.